openPR Logo
Press release

SARI ANNOUNCES CLOSING OF NMS ACQUISITION

Nerviano (Milano - IT), March 28, 2018 – SARI, a Chinese market-leader biotech investment company, is pleased to announce that it has closed the previously announced agreement to acquire the 90% interests in NMS Group S.p.A., effective from today.

SARI is an affiliate of Shanghai Advanced Research Institute, focused on investment in cutting-edge bio-technology and life-science opportunities, especially targeted cancer therapy. The oncology innovation is the mission of NMS Group S.p.A.. Headquartered in Nerviano, near Milano, in Italy it is an organization covering the whole R&D process: from drug discovery, to preclinical research and clinical development up to manufacturing.

“After tremendous efforts from all parties in the last full year, we eventually made a successful closing on the transaction today. Today is the beginning of a new era of innovation and collaboration in pharmaceutical area between Italy and China” – said Mr.Yi Baxian representative of SARI. “We believe that with the integration of Chinese capital and resources, NMS will certainly rejuvenate and generate prosper achievements, which will contribute to the well being of millions of patients.”

The total value of the deal, a mix of equity injection and debt restructuring, is around 300 mln Euro. For this transaction, SARI, as the leading investor, has established a specific fund together with Nanjing Hicin Pharmaceutical Co. Ltd, V-capital Co. Ltd, and Hefei Dongcheng Industry Investment Co. Ltd..

In addition, the Company announces the appointment of the new Board of Directors of NMS Group S.p.A.:
Mr. Andrea Agazzi (Chairman);
Dr. YI Baxian;
Mr. ZHAO Jianghua;
Mr. XU Jun;
Mr. CAO Xichen;
Ms. Cristina Cagnazzi.

“I’m very happy and proud of the path we have done together with Sari until today” - said NMS Group’ Chairman Andrea Agazzi “and I’m very excited about the development projects we are going to start from tomorrow. The deal preserves the Group's business continuity; enhances present resources and the great tradition of excellence that the world has recognized to NMS, even in the most difficult financial times such as it opens the door to new opportunities of growth and industrial and scientific integration within top-class research environment. The trust that investors have placed in NMS people, concretely represented by their great financial effort, must be repaid by excellent results. This is the commitment that the management assumes with today closing.”

For this closing Sari has been assisted by Bank of China International (China) Limited and Shanghai Pudong Science and Technology Investment Co.,LTD (PDSTI) as financial advisors and by Studio Legale Pedersoli as legal advisor. Bank of China Ltd Milan Branch offered help in the transaction. NMS Group has been assisted by Leonardo-Houlihan Lokey as financial advisor and by Avv. Battistella, Partner of CMS as legal advisor.

SARI is an affiliate of Shanghai Advanced Research Institute. SARI focuses on investment in cutting-edge bio-technology and life-science opportunities, especially targeted cancer therapy.
For this transaction, SARI, as the leading investor, has established a specific fund together with Hicin Pharma, V-capital and FeiDong Investment.

NMS Group is the largest company in Italy committed in innovation and research and development in oncology. With more than 420 total employees, NMS Group employs over 200 qualified researchers involved in research and development, to production. The discovery and applied research of Nerviano Medical Sciences define the innovative heart of the Group and make it an important and international reference in the field of personalized therapy. In these recent years the Centre has capitalized its discoveries in international agreements with most representative pharmaceutical and biotech companies worldwide, such as Ignyta for Entrectinib. NMS also provides pre clinical, clinical and production services addressed to local and international markets, through three different companies: Accelera, one of the few companies engaged in preclinical research in Italy; Clioss engaged in clinical development starting from First-Time-In-Man and Nerpharma, dealing with activities from formulation to production of the active principle.

NMS Group – Nerviano Medical Sciences
Chiara Lattuada
+39 333 84.25.690
mail to: chiara.lattuada@nmsgroup.it

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release SARI ANNOUNCES CLOSING OF NMS ACQUISITION here

News-ID: 998388 • Views: 2477

More Releases from NMS Group - Nerviano Medical Sciences

SARI, a Chinese market-leader biotech investment company, today announced it has …
Nerviano (Milano), December 27, 2017 - SARI, a Chinese market-leader biotech investment company, today announced it has entered into an agreement to acquire the 90% interests in Group NMS (NMS). Headquartered in Nerviano, near Milano, Italy, NMS is a group of fully integrated companies owned by Regione Lombardia through Fondazione Regionale per la Ricerca Biomedica, focused on oncology drug discovery, preclinical research, clinical development and manufacturing. “The NMS Group is
Nerviano Medical Sciences presents data regarding a potent new cytotoxic molecul …
NMS-P945 is a potent, innovative and proprietary cytotoxic molecule in the nms pipeline, highly suited to conjugation with targeted antibodies. At the 7th World Summit focused on ADCs (San Diego, CA), Nerviano Medical Sciences presented new data regarding the immunoconjugate drugs field, an area of intense interest in the Oncology R&D sector. During the event NMS researchers described the targeted anticancer effects obtained in preclinical models with an ADC obtained

More Releases for SARI

Modified Starch Market 2019 Analysis By Starch Solution, Cargill, Budi Starch & …
“Modified Starch Market” report provides detailed historical analysis of global market for Modified Starch from 2013-2018, and provides extensive market forecasts from 2018-2028 by region/country and subsectors. It covers the sales volume, price, revenue, gross margin, historical growth and future perspectives in the Modified Starch market. In addition, this report introduces market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in
Future Growth: Global Coconut Gel Market Forecast to 2025 | Livendo Group, CMBev …
Qyresearchreports include new market research report Global Coconut Gel Market Insights, Forecast to 2025 to its huge collection of research reports. This report studies the global market size of Coconut Gel in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Coconut Gel in these regions. This research report categorizes the global Coconut Gel market by players/brands, region, type
Global Modified Starch Market 2018 - Cargill, Ingredion, Bumi Sari Prima
Apex Market Reports, recently published a detailed market research study focused on the “Modified Starch Market” across the global, regional and country level. The report provides 360° analysis of “Modified Starch Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Modified Starch on
Palm Acid Oil Market 2017- Tanimas Group, Bathich Group, Kurnia Sari Utama
Apex Market Reports, recently published a detailed market research study focused on the "Palm Acid Oil Market" across the global, regional and country level. The report provides 360° analysis of "Palm Acid Oil Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Palm Acid Oil industry, and estimates the
Modified Starch Market Report for Period 2022 Ingredion, Bumi Sari Prima, Cargil …
Global Modified Starch market report provides detailed analysis of companies namely Budi Starch & Sweetener, Ingredion, Bumi Sari Prima, Starch Solution, Cargill and Others. This report study includes global market statistics and analysis for example, company performance, historical analysis 2012 to 2016, market forecast 2017 to 2023 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2017 to 2022, etc. Modified starch, also called starch derivatives, is prepared
Palm Acid Oil Market Forecast 2017-2022 Methyl Ester, LIMA group, Kurnia Sari Ut …
Recently published a detailed market study on the "Palm Acid Oil Market" across the global, regional and country level. The report on the global Palm Acid Oil market uses the top-down and bottom-up approaches to define, analyze, and describe the market trends for the next five years. The Palm Acid Oil market report further provides production, capacity, Palm Acid Oil market price per region, gross margin, production cost, for all